SEARCH

SEARCH BY CITATION

References

  • Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1): S1S254. see specifically S11 through S13 for comprehensive database and references to 5-HT7.
  • Angileri FF, Aguennouz M, Conti A, La Torre D, Cardali S, Crupi R et al. (2008). Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2–4 astrocytomas. Cancer 112: 22582266.
  • Brantley EC, Benveniste EN (2008). Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res 6: 675684.
  • Calzolari A, Larocca LM, Deaglio S, Finisguerra V, Boe A, Raggi C et al. (2010). Transferrin receptor 2 is frequently and highly expressed in glioblastomas. Transl Oncol 3: 123134.
  • Candi E, Knight RA, Spinedi A, Guerrieri P, Melino G (1997). A possible growth factor role of IL-6 in neuroectodermal tumours. J Neurooncol 31: 115122.
  • Chang CY, Li MC, Liao SL, Huang YL, Shen CC, Pan HC (2005). Prognostic and clinical implication of IL-6 expression in glioblastoma multiforme. J Clin Neurosci 12: 930933.
  • Choi C, Gillespie GY, Van Wagoner NJ, Benveniste EN (2002). Fas engagement increases expression of IL-6 in human glioma cells. J Neurooncol 56: 1319.
  • Degterev A, Yuan J (2008). Expansion and evolution of cell death programmes. Nat Rev Mol Cell Biol 9: 378390.
  • Gessi S, Sacchetto V, Fogli E, Merighi S, Varani K, Baraldi PG et al. (2010). Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A(3) adenosine receptors. Biochem Pharmacol 79: 14831495.
  • Goswami S, Gupta A, Sharma SK (1998). IL-6-mediated autocrine growth promotion in human glioblastoma multiforme cell line U87MG. J Neurochem 71: 18371845.
  • Hannon J, Hoyer D (2008). Molecular biology of 5-HT receptors. Behav Brain Res 195: 198213.
  • Hirst WD, Price GW, Rattray M, Wilkin GP (1997). Identification of 5-hydroxytryptamine receptors positively coupled to adenylyl cyclase in rat cultured astrocytes. Br J Pharmacol 120: 509515.
  • Juillerat-Jeanneret L, Celerier J, Chapuis Bernasconi C, Nguyen G, Wostl W, Maerki HP et al. (2004). Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma. Br J Cancer 90: 10591068.
  • Kast RE (2000). Tumor necrosis factor has positive and negative self regulatory feed back cycles centered around cAMP. Int J Immunopharmacol 22: 10011006.
  • Kast RE (2005). Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: new insights into the biology of TNF-alpha giving new treatment opportunities – the role of bupropion. Leuk Res 29: 14591463.
  • Kast RE (2007). Melanoma inhibition by cyclooxygenase inhibitors: role of interleukin-6 suppression, a putative mechanism of action, and clinical implications. Med Oncol 24: 16.
  • Kast RE (2009). Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA approved antiemetic aprepitant might retard cerebral glioblastoma growth: a new hypothesis answering an old question. Clin Transl. Oncology 11: 408410.
  • Kast RE (2010). Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug. J Clin Pharm Ther DOI: 10.1111/j.1365-2710.2009.01148.x [Epub ahead of print.
  • Kast RE, Altschuler EL (2006). Current drugs available now for interleukin-6 suppression as treatment adjunct in gllioblastoma: anakinra, aprepitant, mirtazapine and olanzapine. Int J Cancer Res 2: 303314.
  • Kim JY, Kim YJ, Lee S, Park JH (2009). The critical role of ERK in death resistance and invasiveness of hypoxia selected glioblastoma cells. BMC Cancer 9: 27.
  • Kudo M, Jono H, Shinriki S, Yano S, Nakamura H, Makino K et al. (2009). Antitumor effect of humanized anti-interleukin-6 receptor antibody (tocilizumab) on glioma cell proliferation. J Neurosurg 111: 219225.
  • Lieb K, Biersack L, Waschbisch A, Orlikowski S, Akundi RS, Candelario-Jalil E et al. (2005). Serotonin via 5-HT7 receptors activates p38 mitogen-activated protein kinase and protein kinase C epsilon resulting in interleukin-6 synthesis in human U373 MG astrocytoma cells. J Neurochem 93: 549559.
  • Lin HY, Sun M, Tang HY, Lin C, Luidens MK, Mousa SA et al. (2009). L-Thyroxine vs. 3,5,3′-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol 296: C980C991.
  • Liu Q, Li G, Li R, Shen J, He Q, Deng L et al. (2010). IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. J Neurooncol [Epub ahead of print] PubMed PMID: 20361349.
  • Loeffler S, Fayard B, Weis J, Weissenberger J (2005). Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. Int J Cancer 115: 202213.
  • Loew S, Schmidt U, Unterberg A, Halatsch ME (2009). The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. Anticancer Agents Med Chem 9: 703715.
  • Lopez-Gines C, Gil-Benso R, Benito R, Mata M, Pereda J, Sastre J et al. (2008). The activation of ERK1/2 MAP kinases in glioblastoma pathobiology and its relationship with EGFR amplification. Neuropathology 28: 507515.
  • Mahé C, Bernhard M, Bobirnac I, Keser C, Loetscher E, Feuerbach D et al. (2004). Functional expression of the serotonin 5-HT7 receptor in human glioblastoma cell lines. Br J Pharmacol 143: 404410.
  • Marino J, Caballero J (2008). Paliperidone extended-release for the treatment of schizophrenia. Pharmacotherapy 28: 12831298.
  • Maru SV, Holloway KA, Flynn G, Lancashire CL, Loughlin AJ, Male DK et al. (2008). Chemokine production and chemokine receptor expression by human glioma cells: role of CXCL10 in tumour cell proliferation. J Neuroimmunol 199: 3545.
  • Möller HJ (2005). Risperidone: a review. Expert Opin Pharmacother 6: 803818.
  • Opler LA, Feinberg SS (1991). The role of pimozide in clinical psychiatry: a review. J Clin Psychiatry 52: 221233.
  • Owens DG (1994). Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry 55: 2935.
  • Pittalà V, Salerno L, Modica M, Siracusa MA, Romeo G (2007). 5-HT7 receptor ligands: recent developments and potential therapeutic applications. Mini Rev Med Chem 7: 945960.
  • Porcile C, Bajetto A, Barbieri F, Barbero S, Bonavia R, Biglieri M et al. (2005). Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. Exp Cell Res 308: 241253.
  • Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ (2002). Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 21: 84048413.
  • Reimold M, Solbach C, Noda S, Schaefer JE, Bartels M, Beneke M et al. (2007). Occupancy of dopamine D(1), D (2) and serotonin(2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berl) 190: 241249.
  • Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y et al. (1994). Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268: 14031410.
  • Samaras V, Piperi C, Korkolopoulou P, Zisakis A, Levidou G, Themistocleous MS et al. (2007). Application of the ELISPOT method for comparative analysis of IL-6 and IL-10 secretion in peripheral blood of patients with astroglial tumors. Mol Cell Biochem 304: 343351.
  • Samaras V, Piperi C, Levidou G, Zisakis A, Kavantzas N, Themistocleous MS et al. (2009). Analysis of interleukin (IL)-8 expression in human astrocytomas: associations with IL-6, COX-2, VEGF, and microvessel morphometry. Hum Immunol 70: 391397.
  • Sasaki A, Ishiuchi S, Kanda T, Hasegawa M, Nakazato Y (2001). Analysis of interleukin-6 gene expression in primary human gliomas, glioblastoma xenografts, and glioblastoma cell lines. Brain Tumor Pathol 18: 1321.
  • Smith C, Rahman T, Toohey N, Mazurkiewicz J, Herrick-Davis K, Teitler M (2006). Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin receptor. Mol Pharmacol 70: 12641270.
  • Soga F, Katoh N, Inoue T, Kishimoto S (2007). Serotonin activates human monocytes and prevents apoptosis. J Invest Dermatol 127: 19471955.
  • Stegh AH, Kim H, Bachoo RM, Forloney KL, Zhang J, Schulze H et al. (2007). Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev 21: 98111.
  • Stegh AH, Kesari S, Mahoney JE, Jenq HT, Forloney KL, Protopopov A et al. (2008). Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Proc Natl Acad Sci USA 105: 1070310708.
  • Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Böck BC et al. (2008). Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 27: 66466656.
  • Tchirkov A, Rolhion C, Bertrand S, Doré JF, Dubost JJ, Verrelle P (2001). IL-6 gene amplification and expression in human glioblastomas. Br J Cancer 85: 518522.
  • Thomas DR, Hagan JJ (2004). 5-HT7 receptors. Curr Drug Targets CNS Neurol Disord 3: 8190.
  • Tueth MJ, Cheong JA (1993). Clinical uses of pimozide. South Med J 86: 344349.
  • Xu L, Fukumura D, Jain RK (2002). Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGF. J Biol Chem 277: 1136811374.
  • Yip KW, Reed JC (2008). Bcl-2 family proteins and cancer. Oncogene 27: 63986406.
  • Zohrabian VM, Forzani B, Chau Z, Murali R, Jhanwar-Uniyal M (2009). Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. Anticancer Res 29: 119123.